MCID: PNC095
MIFTS: 31

Pancreatic Cancer 3

Categories: Genetic diseases, Endocrine diseases, Cancer diseases, Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreatic Cancer 3

MalaCards integrated aliases for Pancreatic Cancer 3:

Name: Pancreatic Cancer 3 54 71 29
Pancreatic Cancer, Susceptibility to, 3 13
Pnca3 71

Classifications:



External Ids:

OMIM 54 613348
MedGen 40 C3150547
MeSH 42 D010190

Summaries for Pancreatic Cancer 3

UniProtKB/Swiss-Prot : 71 Pancreatic cancer 3: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 3, also known as pancreatic cancer, susceptibility to, 3, is related to mitochondrial complex iii deficiency, nuclear type 5. An important gene associated with Pancreatic Cancer 3 is PALB2 (Partner And Localizer Of BRCA2). The drugs Pancrelipase and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and t cells, and related phenotype is Synthetic lethal with MLN4924 (a NAE inhibitor).

Description from OMIM: 613348

Related Diseases for Pancreatic Cancer 3

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer 3 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 mitochondrial complex iii deficiency, nuclear type 5 9.5 GDNF PALB2

Symptoms & Phenotypes for Pancreatic Cancer 3

Clinical features from OMIM:

613348

GenomeRNAi Phenotypes related to Pancreatic Cancer 3 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.23 GDNF PALB2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.23 GDNF PALB2

Drugs & Therapeutics for Pancreatic Cancer 3

Drugs for Pancreatic Cancer 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 487)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
3
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
5
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
7
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
8
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
9
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
10
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943
11
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Nicotine Approved Phase 4 54-11-5 942 89594
14
Tegafur Approved Phase 4,Phase 2 17902-23-7 5386
15
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
16 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
18 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
19 Anesthetics Phase 4,Phase 3,Phase 2
20 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Liver Extracts Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
24 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1,Phase 2
26 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
28 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
29 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38
s 1 (combination) Phase 4,Phase 3,Phase 2,Phase 1
39 Anticonvulsants Phase 4,Phase 2
40 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
42 Tranquilizing Agents Phase 4,Phase 3,Phase 2
43
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
44 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
45 Adrenergic Agents Phase 4,Phase 2,Phase 3
46 Adrenergic Agonists Phase 4
47 Adrenergic alpha-2 Receptor Agonists Phase 4
48 Adrenergic alpha-Agonists Phase 4
49 Hypnotics and Sedatives Phase 4
50 Autonomic Agents Phase 4,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 852)

id Name Status NCT ID Phase Drugs
1 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
2 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
3 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
4 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
5 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
6 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
7 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
8 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
9 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
10 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
11 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
12 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
13 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
14 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
15 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Not yet recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
16 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
17 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
18 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
19 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
20 A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Unknown status NCT00789633 Phase 3 masitinib (AB1010);placebo
21 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
22 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3 Gemcitabine;Curcumin;Celebrex
23 Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain Unknown status NCT02510066 Phase 3
24 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
25 Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer Unknown status NCT02079623 Phase 3
26 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
27 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
28 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
29 Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
30 Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
31 Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer Unknown status NCT00813696 Phase 3 gemcitabine;cisplatin
32 Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer Unknown status NCT01314027 Phase 3 Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin;adjuvant chemotherapy with gemcitabine
33 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
34 Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine Unknown status NCT00440167 Phase 3 Gemcitabine;Capecitabine;Erlotinib
35 Hyperthermia European Adjuvant Trial Unknown status NCT01077427 Phase 3 Gemcitabine
36 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
37 Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
38 PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen Unknown status NCT00088660 Phase 3
39 Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Unknown status NCT02311439 Phase 2, Phase 3 FOLFIRINOX + CRT
40 Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic Head Unknown status NCT00753441 Phase 2, Phase 3
41 Evaluation of A New Digestive Reconstruction Procedure Following Pancreatoduodenectomy Unknown status NCT01931449 Phase 3
42 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
43 Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery Unknown status NCT01655641 Phase 2, Phase 3 Tranexamic acid
44 The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer Unknown status NCT01332773 Phase 3
45 A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. Completed NCT00035035 Phase 3 GEMZAR;ALIMTA
46 Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer Completed NCT01494506 Phase 3 MM-398;5 Fluorouracil;Leucovorin
47 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
48 An Open Label Study to Evaluate G17DT Compared to Gemcitabine Completed NCT03200821 Phase 3 Gemcitabine
49 Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
50 Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer Completed NCT00192712 Phase 2, Phase 3 irinotecan, gemcitabine

Search NIH Clinical Center for Pancreatic Cancer 3

Genetic Tests for Pancreatic Cancer 3

Genetic tests related to Pancreatic Cancer 3:

id Genetic test Affiliating Genes
1 Pancreatic Cancer 3 29

Anatomical Context for Pancreatic Cancer 3

MalaCards organs/tissues related to Pancreatic Cancer 3:

39
Pancreas, Lung, T Cells, Liver, Testes, Skin, Prostate

Publications for Pancreatic Cancer 3

Variations for Pancreatic Cancer 3

ClinVar genetic disease variations for Pancreatic Cancer 3:

6 (show all 12)
id Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.3549C> G (p.Tyr1183Ter) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs118203998 GRCh37 Chromosome 16, 23614792: 23614792
2 PALB2 NM_024675.3(PALB2): c.1027C> T (p.Gln343Ter) single nucleotide variant Pathogenic,risk factor rs180177097 GRCh38 Chromosome 16, 23635519: 23635519
3 PALB2 NM_024675.3(PALB2): c.1314delA (p.Phe440Leufs) deletion Pathogenic rs515726065 GRCh38 Chromosome 16, 23635232: 23635232
4 PALB2 NM_024675.3(PALB2): c.172_175delTTGT (p.Gln60Argfs) deletion risk factor rs180177143 GRCh38 Chromosome 16, 23637886: 23637889
5 PALB2 PALB2: c.2515-1G> T single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs587776417 GRCh38 Chromosome 16, 23629276: 23629276
6 PALB2 NM_024675.3(PALB2): c.3116delA (p.Asn1039Ilefs) deletion Pathogenic/Likely pathogenic,risk factor rs180177133 GRCh38 Chromosome 16, 23614089: 23614089
7 PALB2 PALB2: c.3202-?_*297del (p.Gly1068_Ser1186delins45) deletion Pathogenic GRCh38 Chromosome 16, 23603162: 23608012
8 PALB2 NM_024675.3(PALB2): c.3256C> T (p.Arg1086Ter) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs587776527 GRCh38 Chromosome 16, 23607958: 23607958
9 PALB2 NM_024675.3(PALB2): c.3497delG (p.Gly1166Valfs) deletion Pathogenic rs180177138 GRCh38 Chromosome 16, 23603523: 23603523
10 PALB2 NM_024675.3(PALB2): c.509_510delGA (p.Arg170Ilefs) deletion Pathogenic rs515726123 GRCh38 Chromosome 16, 23636036: 23636037
11 PALB2 NM_024675.3(PALB2): c.72delG (p.Arg26Glyfs) deletion Pathogenic rs180177142 GRCh38 Chromosome 16, 23638106: 23638106
12 PALB2 NM_024675.3(PALB2): c.757_758delCT (p.Leu253Ilefs) deletion Pathogenic rs180177092 GRCh38 Chromosome 16, 23635788: 23635789

Expression for Pancreatic Cancer 3

Search GEO for disease gene expression data for Pancreatic Cancer 3.

Pathways for Pancreatic Cancer 3

GO Terms for Pancreatic Cancer 3

Biological processes related to Pancreatic Cancer 3 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 8.62 GDNF PALB2

Sources for Pancreatic Cancer 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....